Giorgio Massimini
CMO CanWell Pharma
Seminars
Wednesday 10th March 2027
Unlocking Development of Dual Payload ADC & iADC with Pre-Clinical & Clinical Experiences
11:15 am
- Advancing CAN1012, a novel IFN-a biased TR7 agonist, demonstrating a wide therapeutic window in on-going clinical studies and an ideal payload for iADC
- Highlighting construction of a dual payload iADC currently being tested in the clinical trials
